Sanofi (France)'s Multaq Doubled Deaths from Heart Disease in Study

Published: Nov 15, 2011

Sanofi’s Multaq, approved to treat patients whose hearts intermittently race with quick and inefficient contractions, doubled the risk of death in those with a permanent form of the erratic rhythm, a study found. Stroke and heart failure rates also rose significantly in those given Multaq during the trial of 3,236 patients, a blow for the drug that doctors thought would avoid the risks seen with earlier generations of anti-arrhythmic drugs. The research was halted in July because of the increased danger, and the results were presented today at the American Heart Association’s annual meeting in Orlando, Florida.

Back to news